Does a fourth dose of a SARS-CoV-2 messenger RNA (mRNA)-based vaccine improve anti-SARS-CoV-2 antibody response in solid organ transplant recipients?
This case series study assesses whether a fourth dose of a SARS-CoV-2 messenger RNA (mRNA)–based vaccine is associated with improved anti–SARS-CoV-2 antibody response in solid organ transplant recipients in France.
Kamar et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: